 World First Travel Insurance |
GSK asthma drug cuts symptoms 52%; ready for PhIII
Pharma Times GlaxoSmithKline's mepolizumab is now ready for late-stage testing after turning in a strong performance in Phase II trials assessing the experimental drug in a rare and hard-to-treat form of asthma. The Phase IIb trial was designed to investigate … GSK drug halves attacks in hard-to-treat asthma Drug 'could cut asthma A&E visits' Experimental Asthma Drug Halves Attacks |
View full post on asthma – Google News